Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
A Special Iftar Gathering with Biologix Family
Biologix Participates in the 2nd Saudi Rare Disease Summit, Advocating for Pediatric Neurology Awareness
Biologix participated in the 2nd Saudi Rare Disease Summit held in Riyadh, KSA, on February 16-17, 2024.
Focused on pediatric neurology, particularly CDKL5 Deficiency Disorder and Alpha Mannosidosis, the congress showed the importance of raising awareness and advancing understanding in this specialized field.
The Signal To Noise Ratio: A Saudi Ministry Of Health Rare Disease Moonshot Pledge
Biologix was delighted to sponsor the unique "The Signal To Noise Ratio: A Saudi Ministry Of Health Rare Disease Moonshot Pledge" in collaboration with the Saudi Society Of Clinical Pharmacy as "Gold Sponsor"...Read More
